MMP9 and nonpapillary renal cell carcinoma: Conversely, ccRCC patients with higher expression levels of Cyclin E1 and MMP9 had significantly shorter survival time than patients with low Cyclin E1 and MMP9 expression levels (Fig. 2J, M).